Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.65 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pheniprazine SCHEMBL28842219 | 1.00 | SIGMAR1 (0.65) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| Pheniprazine SCHEMBL13063297 | 1.00 | SIGMAR1 (0.65) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| Pheniprazine SCHEMBL289106 | 0.98 | SIGMAR1 (0.63) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| Pheniprazine SCHEMBL7339052 | 0.98 | SIGMAR1 (0.63) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| Benz(B)Anthracene SCHEMBL11128871 | 0.89 | SIGMAR1 (0.53) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| Pheniprazine SCHEMBL10867258 | 0.89 | NPC1 (0.56) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL30624762 | 0.81 | SIGMAR1 (0.71) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL21243273 | 0.81 | SIGMAR1 (0.73) | SIGMAR1TAAR1SLC18A2SLC6A2MAOA | |
| SCHEMBL8720303 | 0.80 | ACACB (0.47) | SIGMAR1TAAR1SLC18A2SLC6A4CYP2A6 | |
| Methamphetamine SCHEMBL42615 | 0.79 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2SLC6A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| US-12121513-B2 | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | Intrabio Ltd. (GB) | 2024-10-22 | — | — | US | claimed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024098098-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural MedTech Pty Ltd (AU) | 2024-05-16 | — | — | WO | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| US-20230364115-A1 | NOVEL PSYCHEDELIC COMPOSITIONS, DELIVERY SYSTEMS AND THERAPEUTIC USES THEREOF | MYDECINE INNOVATIONS GROUP INC (US) | 2023-11-16 | — | — | US | claimed |
| EP-0797442-B1 | TREATMENT OF OPTIC NEURITIS | MASSACHUSETTS EYE & EAR INFIRM (US) | 2003-05-21 | — | — | EP | claimed |
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS LLC (F/K/A VIVUS, INC.) | 2002-10-31 | — | — | US | claimed |
| WO-2002041883-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0070832-A4 | MICROENCAPSULATED FLUORESCER COMPOSITION, TEST KIT AND SYSTEM FOR IMMUNOASSAY. | ELECTRO NUCLEONICS (US) | 1983-06-17 | — | — | EP | claimed |
| EP-0070832-A1 | MICROENCAPSULATED FLUORESCER COMPOSITION, TEST KIT AND SYSTEM FOR IMMUNOASSAY | ELECTRO-NUCLEONICS, INC. (US) | 1983-02-09 | — | — | EP | claimed |
| US-4372745-A | QUALITATIVE AND QUANTITATIVE ANALYSIS | ELECTRO-NUCLEONICS, INC. (US) | 1983-02-08 | — | — | US | claimed |
| WO-1982002772-A1 | MICROENCAPSULATED FLUORESCER COMPOSITION,TEST KIT AND SYSTEM FOR IMMUNOASSAY | ELECTRO NUCLEONICS (US) | 1982-08-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | HTR5A, HTR1A, MAOA | SIGMAR1 11/4885TAAR1 150/4885SLC18A2 35/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | SIGMAR1 174/4885TAAR1 49/4885SLC18A2 46/4885 |
| US-12121513-B2 | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | HNMT, MAOA, MAOB | SIGMAR1 1620/4885TAAR1 655/4885SLC18A2 30/4885 |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | MAOA, MAOB, TPH1 | SIGMAR1 563/4885TAAR1 55/4885SLC18A2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.